Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gadoterate meglumine
Drug ID BADD_D00992
Description Not Available
Indications and Usage Not Available
Marketing Status Not Available
ATC Code Not Available
DrugBank ID Not Available
KEGG ID D03355
MeSH ID C072417
PubChem ID 6918037
TTD Drug ID Not Available
NDC Product Code 66499-0066; 0407-2943; 67684-2001; 57884-0037; 67684-3001; 65219-088; 67684-2000; 76055-1003; 65219-082; 14335-310; 65219-080; 65219-084; 65219-086
UNII L0ND3981AG
Synonyms gadoterate meglumine | Dotarem
Chemical Information
Molecular Formula C23H42GdN5O13
CAS Registry Number 92943-93-6
SMILES CNCC(C(C(C(CO)O)O)O)O.C1CN(CCN(CCN(CCN1CC(=O)O)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-]. [Gd+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactoid reaction10.01.07.003; 24.06.03.007---
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Anxiety19.06.02.002--
Arrhythmia02.03.02.001---
Blood creatinine increased13.13.01.004--
Bradycardia02.03.02.002---
Bronchospasm10.01.03.012; 22.03.01.004--
Burning sensation08.01.09.029; 17.02.06.001---
Cardiac arrest02.03.04.001--
Coma17.02.09.001---
Conjunctivitis06.04.01.002; 11.01.06.012--
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dysgeusia07.14.03.001; 17.02.07.003--
Extravasation08.01.03.008---
Eyelid oedema06.04.04.004; 10.01.05.001; 23.04.01.003---
Fatigue08.01.01.002--
Feeling cold08.01.09.008---
Feeling hot08.01.09.009---
Headache17.14.01.001--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Injection site inflammation08.02.03.008; 12.07.03.009---
Injection site pain08.02.03.010; 12.07.03.011---
Injection site reaction08.02.03.014; 12.07.03.015--
Lacrimation increased06.08.02.004--
Laryngospasm22.04.02.002--
Malaise08.01.01.003--
Muscular weakness15.05.06.001; 17.05.03.005--
The 1th Page    1 2    Next   Last    Total 2 Pages